J Clin Neurol.  2010 Sep;6(3):117-126. 10.3988/jcn.2010.6.3.117.

Cost-Effectiveness of Recombinant Tissue Plasminogen Activator in the Management of Acute Ischemic Stroke: A Systematic Review

• Jung KT
• Shin DW
• Lee KJ
• Oh M

• KMID: 1462847
• DOI: http://doi.org/10.3988/jcn.2010.6.3.117

Abstract

BACKGROUND AND PURPOSE
This work was undertaken to review the current cost-effectiveness analysis data on thrombolysis by intravenous (IV) therapy with recombinant tissue plasminogen activator (rtPA) for acute ischemic stroke.
METHODS
PubMed was searched for articles published between 1995 and 2008. The cost-effectiveness analysis data from eight eligible studies were reviewed, paying particular attention to their modeling assumptions and the quality of the source data.
RESULTS
The reviewed studies were from six countries: USA (n=2), UK (n=2), Canada (n=1), Australia (n=1), Spain (n=1), and Denmark (n=1); most were performed from the healthcare-system and/or societal perspectives. IV rtPA was associated with an acceptable increase in short-term cost [range: US$ 36-236/patient; US$ 29,148-55,591/quality-adjusted life-years (QALYs)], and a net long-term cost saving that was higher from a societal perspective (range: -US$ 12,043 to -US$ 630/patient; -US$ 207,253 to -US$ 21,938/QALYs) than from a healthcare-system perspective (range: -US$ 5,811 to -US$ 5,415/patient; -US$ 41,137 to -US$ 4,662/QALYs).
CONCLUSIONS
IV rtPA seems to be a cost-effective strategy for the management of acute ischemic stroke, and might reduce the associated healthcare costs as well as patients' disabilities. Further cost-effectiveness research and the development of a public health strategy are warranted to optimize the use of rtPA in Korea.

Keyword

thrombolysis; stroke; recombinant tissue plasminogen activator; cost-effectiveness analysis

MeSH Terms

Australia
Canada
Cost Savings
Denmark
Health Care Costs
Korea
Public Health
Spain
Stroke
Tissue Plasminogen Activator
Tissue Plasminogen Activator

Reference

1. Kim HC, Choi DP, Ahn SV, Nam CM, Suh I. Six-year survival and causes of death among stroke patients in Korea. Neuroepidemiology. 2009. 32:94–100.

2. Kim JS, Choi-Kwon S, Kwon SU, Lee HJ, Park KA, Seo YS. Factors affecting the quality of life after ischemis stroke: young versus old patients. J Clin Neurol. 2005. 1:59–68.

3. Bergman L, van der Meulen JH, Limburg M, Habbema JD. Costs of medical care after first-ever stroke in The Netherlands. Stroke. 1995. 26:1830–1836.

4. Saka O, Serra V, Samyshkin Y, McGuire A, Wolfe CC. Cost-effectiveness of stroke unit care followed by early supported discharge. Stroke. 2009. 40:24–29.

5. Ebrahim S. Cost-effectiveness of stroke prevention. Br Med Bull. 2000. 56:557–570.

6. Lindgren P, Buxton M, Kahan T, Poulter NR, Dahlöf B, Sever PS, et al. Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). Eur J Cardiovasc Prev Rehabil. 2005. 12:29–36.

7. Lundkvist J, Ekman M, Kartman B, Carlsson J, Jönsson L, Lithell H. The cost-effectiveness of candesartan-based antihypertensive treatment for the prevention of nonfatal stroke: results from the Study on COgnition and Prognosis in the Elderly. J Hum Hypertens. 2005. 19:569–576.

8. Sullivan PW, Arant TW, Ellis SL, Ulrich H. The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US. Pharmacoeconomics. 2006. 24:1021–1033.

9. Meenan RT, Saha S, Chou R, Swarztrauber K, Krages KP, O'Keefee-Rosetti M, et al. Effectiveness and cost-effectiveness of echocardiography and carotid imaging in the management of stroke. Evid Rep Technol Assess (Summ). 2002. 1–10.

10. Meenan RT, Saha S, Chou R, Swarztrauber K, Pyle Krages K, O'Keeffe-Rosetti MC, et al. Cost-effectiveness of echocardiography to identify intracardiac thrombus among patients with first stroke or transient ischemic attack. Med Decis Making. 2007. 27:161–177.

11. Wilson RD, Murray PK. Cost-effectiveness of screening for deep vein thrombosis by ultrasound at admission to stroke rehabilitation. Arch Phys Med Rehabil. 2005. 86:1941–1948.

12. Patil CG, Long EF, Lansberg MG. Cost-effectiveness analysis of mechanical thrombectomy in acute ischemic stroke. J Neurosurg. 2009. 110:508–513.

13. Fagan SC, Morgenstern LB, Petitta A, Ward RE, Tilley BC, Marler JR, et al. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group. Neurology. 1998. 50:883–890.

14. Sinclair SE, Frighetto L, Loewen PS, Sunderji R, Teal P, Fagan SC, et al. Cost-Utility analysis of tissue plasminogen activator therapy for acute ischaemic stroke: a Canadian healthcare perspective. Pharmacoeconomics. 2001. 19:927–936.

15. Chambers MG, Koch P, Hutton J. Development of a decision-analytic model of stroke care in the United States and Europe. Value Health. 2002. 5:82–97.

16. Sandercock P, Berge E, Dennis M, Forbes J, Hand P, Kwan J, et al. Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs. Stroke. 2004. 35:1490–1497.

17. Stahl JE, Furie KL, Gleason S, Gazelle GS. Stroke: effect of implementing an evaluation and treatment protocol compliant with NINDS recommendations. Radiology. 2003. 228:659–668.

18. Moodie ML, Carter R, Mihalopoulos C, Thrift AG, Chambers BR, Donnan GA, et al. Trial application of a Model of Resource Utilization, Costs, and Outcomes for Stroke (MORUCOS) to assist priority setting in stroke. Stroke. 2004. 35:1041–1046.

19. Mar J, Begiristain JM, Arrazola A. Cost-effectiveness analysis of thrombolytic treatment for stroke. Cerebrovasc Dis. 2005. 20:193–200.

20. Ehlers L, Andersen G, Clausen LB, Bech M, Kjolby M. Cost-effectiveness of intravenous thrombolysis with alteplase within a 3-hour window after acute ischemic stroke. Stroke. 2007. 38:85–89.

21. Wade WE. Cost-effectiveness of venous thrombosis prophylaxis following ischemic stroke: an assessment of currently available literature. Thromb Res. 1998. 89:199–202.

22. Sarasin FP, Gaspoz JM, Bounameaux H. Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack. Arch Intern Med. 2000. 160:2773–2778.

23. Matchar DB, Samsa GP, Liu S. Cost-effectiveness of antiplatelet agents in secondary stroke prevention: the limits of certainty. Value Health. 2005. 8:572–580.

24. Shah H, Gondek K. Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis. Clin Ther. 2000. 22:362–370.

25. Kane K, Andary MT, Turk M, Goldberg G. Cost-effectiveness in stroke rehab. Arch Phys Med Rehabil. 1996. 77:521.

26. Keith RA. Rehabilitation after stroke: cost-effectiveness analyses. J R Soc Med. 1996. 89:631–633.

27. van Exel NJ, Koopmanschap MA, Scholte op, Niessen LW, Huijsman R. Cost-effectiveness of integrated stroke services. QJM. 2005. 98:415–425.

28. Launois R, Giroud M, Mégnigbêto AC, Le Lay K, Présenté G, Mahagne MH, et al. Estimating the cost-effectiveness of stroke units in France compared with conventional care. Stroke. 2004. 35:770–775.

29. Adams HP Jr, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke. 2007. 38:1655–1711.

30. National Institute for Health and Clinical Excellence. 2008. Stroke: Diagnosis and initial management of acute stroke and transient ischaemic attack (TIA).

31. Holloway RG, Benesch CG, Rahilly CR, Courtright CE. A systematic review of cost-effectiveness research of stroke evaluation and treatment. Stroke. 1999. 30:1340–1349.

32. Tseng MC, Chang KC. Cost-effectiveness analysis of tissue plasminogen activator for acute ischemic stroke: a comparative review. Acta Neurol Taiwan. 2004. 13:149–155.

33. Korean Exchange Bank [cited]. Available from:http://inflationdata.com/.

34. Inflationdata.com. [cited]. Available from:http://inflationdata.com/.

35. Buxton MJ, Drummond MF, Van Hout BA, Prince RL, Sheldon TA, Szucs T, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ. 1997. 6:217–227.

36. Slot KB, Berge E, Dorman P, Lewis S, Dennis M, Sandercock P. Oxfordshire Community Stroke Project, the International Stroke Trial (UK): Lothian Stroke Register. Impact of functional status at six months on long term survival in patients with ischaemic stroke: prospective cohort studies. BMJ. 2008. 336:376–379.

37. Eriksson M, Norrving B, Terént A, Stegmayr B. Functional outcome 3 months after stroke predicts long-term survival. Cerebrovasc Dis. 2008. 25:423–429.

38. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. Second European-Australasian Acute Stroke Study Investigators. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (EC-ASS II). Lancet. 1998. 352:1245–1251.

39. Dirks M, Niessen LW, Huijsman R, van Wijngaarden J, Minkman MM, Franke CL, et al. Promoting Acute Thrombolysis for Ischaemic Stroke (PRACTISE). Int J Stroke. 2007. 2:151–159.

40. Choi JC, Kang SY, Kang JH, Ko YJ, Bae JM. Are in-Hospital Delays Important Obstacles In Thrombolytic Therapy Following Acute Ischemic Stroke? J Clin Neurol. 2007. 3:71–78.

41. Bang OY. Multimodal MRI for ischemic stroke: from acute therapy to preventive strategies. J Clin Neurol. 2009. 5:107–119.

42. Alberts MJ, Hademenos G, Latchaw RE, Jagoda A, Marler JR, Mayberg MR, et al. Recommendations for the establishment of primary stroke centers. Brain Attack Coalition. JAMA. 2000. 283:3102–3109.

43. Alberts MJ, Latchaw RE, Selman WR, Shephard T, Hadley MN, Brass LM, et al. Recommendations for comprehensive stroke centers: a consensus statement from the Brain Attack Coalition. Stroke. 2005. 36:1597–1616.